Transplantation Market Size

Global Transplantation Market Overview

The Transplantation Market Size was valued at USD 14.1 Billion in 2022 and is projected to grow from USD 15.4 Billion in 2023 to USD 31.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.50% during the forecast period (2023 - 2032). Growing need for innovative tissue transplantation products, organ transplantation to address organ failure, and growing need for transplantable organs, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Transplantation Market Trends

• Growing demand for novel tissue transplantation products and organ transplantation for the treatment of organ failure is driving the market growth

One of the main drivers of market expansion is the rising need for innovative tissue transplantation products and organ transplantation for the treatment of organ failure. Common causes of organ failure include severe trauma, blood loss, poisoning, drug addiction, leukemia, sepsis, and other acute disorders. Globally, there is a strong demand for tissue and organ transplantation, particularly for the kidney, heart, liver, and lungs. Organ failure can be brought on by a variety of factors, including poor eating habits, alcohol intake, inactivity, and drug usage. Thus, a boost in transplantation product demand is anticipated shortly. Strong immunosuppressive medications are administered to transplant recipients after surgery, weakening their immune systems and making them more susceptible to infectious infections. This can be attributable to the drop in transplantation rates that has occurred in many nations as a result of the COVID-19 issue. The scarcity of resources during the pandemic, such as primary protective equipment, intensive care units, and blood products, has also been linked to the sharp decrease in market income in 2020.    

The global growth in the need for organ transplants can be attributed to an increase in the prevalence of acute diseases, which in turn causes an increase in the number of organ failures. For instance, diabetes and high blood pressure are two of the most common causes of end-stage renal disease, for which kidney transplantation or dialysis are the only curative options. There were around 122,913 patients nationwide who registered with the U.S. Department of Health & Human Services. As a result, there is a huge demand for cutting-edge transplantation goods to address organ failure. The Health Resources and Services Administration (HRSA) of the United States government launched an initiative on the modernization of the transplantation network and organ procurement in March 2023 to address these issues.  This concept focuses on the publication of fresh information about organ donors and transplants.

The launch of technologically sophisticated goods and the rise in the number of tissue banks are two of the key market-driving factors. But some of the constraints, such the lack of organ donors for transplant surgeries, are anticipated to slow market expansion. The supply and demand of organs for the treatment of organ failure are vastly out of balance. The U.S. Department of Health & Human Services estimates that there were about 43,201 Americans in need of kidney transplants in 2019. But only 23,401 kidney transplant operations were carried out in 2019. Many people are discouraged from making donations due to lack of understanding about organ donation as well as religious and cultural beliefs. Therefore, it is anticipated that the lack of organs for the treatment of organ failure will negatively impact market growth. Thus, driving the Transplantation market revenue.

Transplantation Market Segment Insights

Transplantation Product Type Insights

The Market segments of Transplantation, based on Product Type, includes tissue products, immunosuppressive drugs, and preservation solutions. Tissue products segment dominated the global market in 2022. Tissue products, immunosuppressants, and preservation solutions are the main products utilized during tissue or organ transplantation. The expansion of the segment is related to the rising number of transplantations, including those involving orthopedic soft tissues, heart valves, bone marrow, and cochlear implants. New product development is also promoting market expansion.

Transplantation Application Insights

The Transplantation Market segmentation, based on Application, includes organ transplantation and tissue transplantation. Tissue transplantation segment dominated the global market in 2022. This is because the most frequent surgical procedures conducted around the world involve replacing the skin, cornea, bones, heart valves, tendons, nerves, and veins. The demand for tissue products is anticipated to increase as a result of the rise in burn and accident cases. Spain reported 102,362 injury accidents, according to the European Road Safety Observatory study. Consequently, the need for tissue transplantation has increased.

Transplantation End User Insights

The Market segmentation of Transplantation, based on End User, includes hospitals, transplantation centers, and others. Hospitals segment dominated the Transplantation Market in 2022. Hospitals serve as the major treatment settings for many organ and tissue transplant surgeries. Further predicted growth drivers include the emergence of hospitals with advanced infrastructure. Most of these facilities have access to clear databases that can be used to check on the availability of organs for quick medical action.

Figure 1: Transplantation Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Transplantation Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Transplantation Market dominated this market in 2022 (45.80%). The expansion of the market is being supported by highly developed healthcare facilities and the local presence of numerous major biotechnology and medical device businesses, including Stryker, Arthrex, Inc., Zimmer Biomet, Medtronic, and Novartis AG. In the past ten years, there has been a growing disparity between the availability and demand of organs, such as kidneys, livers, and hearts, for transplantation. However, governments and non-governmental organizations (NGOs) from different nations are taking steps to motivate individuals to donate organs and save lives. Further, the U.S. market of transplantation held the largest market share, and the Canada market of transplantation was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: TRANSPLANTATION MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Transplantation market accounted for the healthy market share in 2022. Over the projection period, it is anticipated that the market will grow due to the increased prevalence of chronic disorders. Over the course of the forecast period, it is anticipated that prominent market participants will debut more products. Further, the German market of transplantation held the largest market share, and the U.K market of transplantation was the fastest growing market in the European region

The Asia Pacific Transplantation market is expected to register significant growth from 2023 to 2032. This is due to the expanding stem cell research to create tissue and organs in vitro as well as the expanding healthcare infrastructure in Asian nations including India, Thailand, the Philippines, and Indonesia. Moreover, China’s market of transplantation held the largest market share and the Indian market of transplantation was the fastest growing market in the Asia-Pacific region.

Transplantation Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of transplantation, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Transplantation industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Transplantation industry to benefit clients and increase the market sector. In recent years, the Transplantation industry has offered some of the most significant advantages to medicine. Major players in the Transplantation market, including Novartis AG, Teva Pharmaceutical Industries Ltd., Arthrex, Inc., Veloxis Pharmaceuticals, Inc. (Asahi Kasei Corporation), BioLife Solutions, TransMedics, F., Hoffmann-La Roche Ltd, Zimmer Biomet, and Astellas Pharma Inc., are attempting to increase market demand by investing in research and development Applications.

A manufacturer of medical devices, Orthofix Medical Inc. (Orthofix), formerly known as Orthofix International NV, offers reconstruction and regenerative musculoskeletal solutions to doctors all over the world. Products for fracture management, regenerative products and tissue forms, paediatric and limb reconstruction, motion preservation and fixation implant devices, and foot and ankle products are among the company's top offerings. In order to reach hospitals, doctors, integrated health delivery systems, ambulatory surgery centers, and other purchasing groups worldwide, Orthofix markets its products both directly and through a network of distributors. In addition to the US, UK, Brazil, Italy, France, and Germany, it also has facilities there. United States-based Orthofix is based in Lewisville, Texas. The fiberFUSE Strip, a cutting-edge demineralized fiber bone-graft product including cancellous bone, was introduced by Orathofix Medical Inc. in July 2021 and was used to implant the first patient.

Amnio Technology is the owner of a tissue-grafting business set up to support the production and supply of amniotic tissue allografts. Human amniotic membranes and fluid are used to create the company's product, which covers and protects wounds, enables patients to receive therapy for injuries, flaws, and repairs, and enhances their quality of life. PalinGen Dual-Layer Membrane and Dual Layer PalinGen X-Membrane were two new PalinGen membrane products introduced by Amnio Technology in February 2022. The novel allografts are minimally altered, homologous usage, and chorion-free, just like the complete line of PalinGen membrane products.

Key Companies in the market of transplantation include

• 
  Novartis AG


• Teva Pharmaceutical Industries Ltd.


• Arthrex, Inc.


• Veloxis Pharmaceuticals, Inc. (Asahi Kasei Corporation)


• BioLife Solutions


• TransMedics


• 
  Hoffmann-La Roche Ltd


• Zimmer Biomet


• Astellas Pharma Inc.

Transplantation Industry Developments

February 2022 Opus BA, a synthetic bioactive bone graft product from Orthofix Medical, was introduced for cervical and lumbar spine fusion treatments. Gaps or cavities in the skeletal system can be filled with the Opus BA solution.

May 2022 With MTF Biologics, Orthofix Medical expanded and renewed their collaboration. The partnership comprises a development deal to create a demineralized bone matrix (DBM), which Orthofix will market under the Legacy brand name, and an extension agreement to prolong Orthofix's exclusive marketing rights to the Trinity allograft line through 2032.

March 2022 In order to distribute Genex Bone Graft Substitute with its novel mixing technology and delivery options exclusively in the United States, Zimmer Biomet and Biocomposites engaged into a multi-year partnership.

January 2022 Alnylam and Novartis AG worked together with the goal of investigating targeted medicine to improve liver function. Alnylam's siRNA technology offers an alternative for those with liver failure because it's designed to encourage the creation of functional liver cells..

Transplantation Market Segmentation

Transplantation Product Type Outlook

• Tissue Products


• Immunosuppressive Drugs


• Preservation Solutions

Transplantation Application Outlook

• Organ Transplantation


• Tissue Transplantation

Transplantation End User Outlook

• Hospitals


• Transplantation Centers


• Others

Transplantation Regional Outlook

• North America
  
  
  
  • U.S.
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America